Miconazole mucoadhesive tablet for oropharyngeal candidiasis

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 1, 2011, Pages 13-17

  Lalla, Rajesh V ^a   Bensadoun, René Jean ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Loramyc ; miconazole mucoadhesive tablet; Oravig ; oropharyngeal candidiasis

Indexed keywords

CLOTRIMAZOLE; LORAMYC; MICONAZOLE; ORAVIG; UNCLASSIFIED DRUG; WARFARIN;

ANEMIA; APPLICATION SITE DISCOMFORT; APPLICATION SITE PAIN; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; COUGHING; CREAM; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; GEL; GINGIVA DISEASE; GINGIVA PAIN; GLOSSODYNIA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MOUTH DISCOMFORT; MOUTH PAIN; MOUTH ULCER; MUCOADHESION; NAUSEA; OINTMENT; OROPHARYNX CANDIDIASIS; SINGLE DRUG DOSE; TABLET FORMULATION; TASTE DISORDER; TONGUE ULCER; TOOTH PAIN; TREATMENT DURATION; TREATMENT INDICATION; TROCHE; UPPER ABDOMINAL PAIN; VIRUS LOAD; VOMITING; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; EUROPE; HUMANS; MICONAZOLE; MOUTH MUCOSA; OROPHARYNX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TABLETS; UNITED STATES;

EID: 78650636065     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.152     Document Type: Article

References (8)

1. Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien HC, Patton LL. Incidence of oral candidiasis and oral hairy leukoplakia in HIV-infected adults in North Carolina. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 99(1), 39-47 (2005). (Pubitemid 39647002)
2. Blignaut E. Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients. Mycopathologia 163(2), 67-73 (2007).
3. Lalla RV, Latortue MC, Hong CH, et al. Fungal Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of oral fungal infections in patients receiving cancer Therapy. Suppor. Care Cancer 18(8), 985-992 (2010).
4. Gligorov J, Bastit L, Gervais H, et al.; on behalf the Candidoscope Study Group. Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the french candidoscope study. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2010.02.006 (2010). (Epub ahead of print).
5. Pappas PG, Kauffman CA, Andes D, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48(5), 503-535 (2009).
6. Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses 53(5), 434-437 (2010).
7. Vazquez JA, Patton LL, Epstein JB, et al. Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad Efficacy and Safety (SMiLES). HIV Clinical Trials. HIV Clin. Trials 11(4), 186-196 (2010).
8. Bensadoun RJ, Daoud J, El Gueddari B, et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, Phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 112(1), 204-211 (2008).